HUP0103578A2 - Az oszteoprotegerin-ligand aktivitásának csökkentő szabályozására szolgáló eljárás - Google Patents

Az oszteoprotegerin-ligand aktivitásának csökkentő szabályozására szolgáló eljárás

Info

Publication number
HUP0103578A2
HUP0103578A2 HU0103578A HUP0103578A HUP0103578A2 HU P0103578 A2 HUP0103578 A2 HU P0103578A2 HU 0103578 A HU0103578 A HU 0103578A HU P0103578 A HUP0103578 A HU P0103578A HU P0103578 A2 HUP0103578 A2 HU P0103578A2
Authority
HU
Hungary
Prior art keywords
opgls
subject
opgl
well
modified
Prior art date
Application number
HU0103578A
Other languages
English (en)
Inventor
Jesper Haaning
Torben Halkier
Original Assignee
Pharmexa A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S filed Critical Pharmexa A/S
Publication of HUP0103578A2 publication Critical patent/HUP0103578A2/hu
Publication of HUP0103578A3 publication Critical patent/HUP0103578A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A találmány tárgyát képezi eljárás az oszteoprotegerin-ligand (OPGL)csökkentő szabályozására (<down-regulate<) azáltal, hogy acsontritkulásban szenvedő vagy csontritkulásra hajlamos betegekbenantitestet termeltetnek az OPGL ellen. A találmány tárgyát képeziktovábbá az eljáráshoz alkalmazható módosított OPGL-ek előállításáraszolgáló eljárások, továbbá maguk a módosított OPGL-ek. A találmánytárgyát képezik továbbá a módosított OPGL-eket kódolónukleinsavfragmensek, továbbá a nukleinsavfragmenseket hordozóvektorok, valamint az ezekkel transzformált sejtek és sejtvonalak. Atalálmány tárgyát képezi továbbá a találmány szerinti eljárásbanalkalmazható OPGL-analógok azonosítására szolgáló eljárás, valamint amódosított OPGL-eket tartalmazó készítmények és az OPGL-analógokatkódoló nukleinsavakat tartalmazó készítmények. A találmány szerintimegoldás a csontritkulás (oszteoporózis) és más, a csontszövetfolyamatos csökkenésével járó betegségek gyógyításának ésmegelőzésének területén alkalmazható. Ó
HU0103578A 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity HUP0103578A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
PCT/DK1999/000481 WO2000015807A1 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Publications (2)

Publication Number Publication Date
HUP0103578A2 true HUP0103578A2 (hu) 2002-01-28
HUP0103578A3 HUP0103578A3 (en) 2005-11-28

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103578A HUP0103578A3 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Country Status (24)

Country Link
US (2) US6645500B1 (hu)
EP (1) EP1114166B1 (hu)
JP (1) JP2002525060A (hu)
KR (1) KR100671036B1 (hu)
CN (1) CN1318105A (hu)
AT (1) ATE291628T1 (hu)
AU (1) AU754971B2 (hu)
CA (1) CA2343654A1 (hu)
CZ (1) CZ2001789A3 (hu)
DE (1) DE69924392T2 (hu)
EE (1) EE200100149A (hu)
ES (1) ES2239457T3 (hu)
HK (1) HK1040261A1 (hu)
HR (1) HRP20010188A2 (hu)
HU (1) HUP0103578A3 (hu)
ID (1) ID28386A (hu)
IL (2) IL141588A0 (hu)
NO (1) NO20011304L (hu)
NZ (1) NZ510508A (hu)
PL (1) PL196790B1 (hu)
PT (1) PT1114166E (hu)
SK (1) SK3062001A3 (hu)
TR (1) TR200100737T2 (hu)
WO (1) WO2000015807A1 (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132304A0 (en) * 1997-04-16 2001-03-19 Amgen Inc Osteoprotegerin binding proteins and receptors
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
IL141588A0 (en) * 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
DE60043346D1 (de) * 1999-07-28 2009-12-31 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
SK287468B6 (sk) * 2000-02-21 2010-10-07 H. Lundbeck A/S Použitie analógu autológneho Aß alebo APP polypeptidu živočícha, analóg, fragment nukleovej kyseliny, vektor, transformovaná bunka, bunková línia a kompozície
KR100879810B1 (ko) * 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 아밀로이드의 하향-조절을 위한 신규한 방법
AU3868001A (en) † 2000-02-23 2001-09-03 Amgen Inc Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
JP2004520011A (ja) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体
WO2002024228A1 (fr) * 2000-09-21 2002-03-28 Center For Advanced Science And Technology Incubation, Ltd. Méthode de régulation de la formation d'ostéoclastes
MXPA03002443A (es) 2000-09-22 2004-12-06 Immunex Corp Ensayos de clasificacion para agonistas o antagonistas del activador receptor de nf-kb.
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
EP1385532A4 (en) * 2001-03-22 2004-12-15 Barnes Jewish Hospital STIMULATION OF THE OSTEOGENESIS WITH RANG-LIGAND FUSION PROTEINS
EP1377610A2 (en) 2001-04-03 2004-01-07 Société des Produits Nestlé S.A. Osteoprotegerin in milk
CA2451955C (en) * 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
JP2005530482A (ja) 2002-01-04 2005-10-13 ゼンコー・インコーポレイテッド ドミナントネガティブタンパク質およびそれらの用法
EP1560843A4 (en) * 2002-01-04 2006-09-06 Xencor Inc NEW VARIANTS OF RANKL PROTEIN
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
CA2481074A1 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
WO2004052233A2 (en) 2002-12-10 2004-06-24 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
CN1960752A (zh) * 2004-06-02 2007-05-09 赛托斯生物技术公司 非人类tnf－肽的载体偶联物的医药用途
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
EP3029061B1 (en) * 2008-06-18 2017-09-13 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
WO2024054566A1 (en) * 2022-09-07 2024-03-14 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
WO1995005879A1 (en) 1993-08-27 1995-03-02 The Dow Chemical Company Process for the separation of enantiomers
AU7353094A (en) * 1994-04-01 1995-10-23 University Of Utah, The Molecular cloning and expression of a gamma-interferon inducible activator of the proteasome
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
DE69738811D1 (de) * 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
DE69738841D1 (de) * 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
IL132304A0 (en) * 1997-04-16 2001-03-19 Amgen Inc Osteoprotegerin binding proteins and receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
IL141588A0 (en) * 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
NZ510508A (en) 2005-05-27
DE69924392D1 (de) 2005-04-28
NO20011304L (no) 2001-05-15
HRP20010188A2 (en) 2002-04-30
HUP0103578A3 (en) 2005-11-28
AU5617399A (en) 2000-04-03
EP1114166A1 (en) 2001-07-11
EE200100149A (et) 2002-08-15
CA2343654A1 (en) 2000-03-23
PL346698A1 (en) 2002-02-25
DE69924392T2 (de) 2006-03-09
CZ2001789A3 (cs) 2001-08-15
ID28386A (id) 2001-05-17
PT1114166E (pt) 2005-08-31
NO20011304D0 (no) 2001-03-14
HK1040261A1 (zh) 2002-05-31
KR20010085807A (ko) 2001-09-07
CN1318105A (zh) 2001-10-17
IL141588A (en) 2008-07-08
IL141588A0 (en) 2002-03-10
EP1114166B1 (en) 2005-03-23
ES2239457T3 (es) 2005-09-16
KR100671036B1 (ko) 2007-01-18
ATE291628T1 (de) 2005-04-15
SK3062001A3 (en) 2002-02-05
WO2000015807A1 (en) 2000-03-23
JP2002525060A (ja) 2002-08-13
TR200100737T2 (tr) 2001-07-23
AU754971B2 (en) 2002-11-28
US20040115199A1 (en) 2004-06-17
US6645500B1 (en) 2003-11-11
PL196790B1 (pl) 2008-01-31

Similar Documents

Publication Publication Date Title
HUP0103578A2 (hu) Az oszteoprotegerin-ligand aktivitásának csökkentő szabályozására szolgáló eljárás
HUP0300067A2 (en) Novel method for down-regulation of amyloid
MXPA02006145A (es) Metodo para el aislamiento de arn de especimenes de tejido incluido en parafina fijo en formalina.
MXPA02000192A (es) Composiciones y metodos para la terapia y diagnostico de cancer de pulmon.
HUP0400231A2 (hu) Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények
HUP0103758A2 (hu) Neurotróf faktorok
WO1998020865A3 (en) Therapeutic uses for nitric oxide inhibitors
JP2001513533A5 (hu)
NZ597965A (en) Methods of preparing and using stem cell compositions and kits comprising the same
HUP0300588A2 (hu) Rekombináns véralvadási faktorok előállítása humán sejtvonalakon
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
Ballal et al. Dissociation and reconstitution of chromatin without appreciable degradation of the proteins
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
Blattler et al. Dissociation of urease by glycol and glycerol
HUP9901551A2 (hu) Daganatnövekedést gátló készítmények, eljárás előállításukra, és alkalmazásuk
ATE85345T1 (de) Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
Pany-Kucera et al. Social Relations, Deprivation and Violence at Schleinbach, Lower Austria. Insights from an Interdisciplinary Analysis of the Early Bronze Age Human Remains
WO2002078526A3 (en) Cancer-testis antigens
WO2001019966A3 (en) Isolation of muscle-derived stem cells and uses therefor
Woodcock et al. Characteristics of enzymatic DNA methylation in cultured cells of human and hamster origin, and the effect of DNA replication inhibition
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
EP1050542A4 (en) NEW POTASSIUM CHANNEL PROTEIN
Vaes et al. The precursor of bone collagenase and its activation
EP0770137A4 (en) IMPROVEMENTS IN PROTEIN PRODUCTION IN HOST CELLS
Gjaldbaek et al. Does urine from stone-formers contain macromolecules which promote the crystal growth rate of calcium oxalate crystals in vitro?

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees